Abstract
Hereditary papillary renal carcinoma (HPRC) is a highly penetrant hereditary renal cancer syndrome caused by germline missense mutations in the c-MET proto-oncogene. HPRC is clinically characterized by multiple bilateral papillary renal-cell carcinomas. Here we report a family with a novel missense mutation in c-MET. The original pathology report of four primary kidney cancers (1988–1997) revealed renal-cell carcinoma. A revised report described multiple adenomas and papillary renal-cell carcinomas with focal clear cells and a mixture of type 1 and type 2 pattern, emphasizing the importance of revised pathology examinations in possible hereditary renal-cell carcinomas especially when described before 1997.
References
Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 5:381–393
Verine J, Pluvinage A, Bousquet G, Lehmann-Che J, de Bazelaire C, Soufir N, Mongiat-Artus P (2010) Hereditary renal cancer syndromes: an update of a a systemitic review. Eur Urol 58:701–710
Trusolino L, Bertotti A, Comoglio PM (2010) MET signaling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834–848
Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, Warren MB, Choyke PL, Torres-Cabala CA, Merino MJ, Brunet J, Berez V, Borras J, Sesia G, Middelton L, Phillips JL, Stolle C, Zbar B, Pautler SE, Linehan WM (2004) Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the MET proto-oncogene. J Urol 172:1256–1261
Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergenheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richads S, Lips CJM, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73
Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistocheical study of 105 tumors. Mod Pathol 10:537
Schmidt LS, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HPH, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343–2350
Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, Terrone C, Rocca-Rossetti S, Comoglio P, Flavia Di Renzo M (1999) Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82:640–643
Shu HK, Chang CM, Ravi L, Ling L, Castellano CM, Walter E, Pelley RJ, Kung HJ (1994) Modulation of erbB kinase activity and ancogenic potential by single point mutations in the glycine loop of the catalytic domain. Mol Cell Biol 14:6868–6878
Jensen AØ, Sværke C, Farkas D, Peersen L, Kragballe K, Sørensen HS (2010) Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 90:474–479
Conflict of interest
The authors declare: No conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wadt, K.A.W., Gerdes, AM., Hansen, T.V.O. et al. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. Familial Cancer 11, 535–537 (2012). https://doi.org/10.1007/s10689-012-9542-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-012-9542-6